Skip to main content

Advertisement

Articles

Page 5 of 40

  1. Molecular subtyping of urothelial cancer (UC) has significantly advanced the understanding of bladder tumor heterogeneity and development of prognostic and predictive biomarkers. Evolving evidence across cance...

    Authors: Thiago Vidotto, Sarah Nersesian, Charles Graham, D. Robert Siemens and Madhuri Koti

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:148

    Content type: Research article

    Published on:

  2. Tumor-associated macrophages (TAMs) are the major component of tumor-infiltrating immune cells. Macrophages are broadly categorized as M1 or M2 types, and TAMs have been shown to express an M2-like phenotype. ...

    Authors: Chanju Lee, Hyunju Jeong, Younghyeon Bae, Kyungmoon Shin, Sinwoo Kang, Hwikyung Kim, Jayoung Oh and Hyunsu Bae

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:147

    Content type: Research article

    Published on:

  3. Pet dogs spontaneously develop lymphoma. An anthracycline-based multidrug chemotherapy regimen represents the treatment cornerstone; however, cure is rarely achieved. We have been treating dogs with B-cell lym...

    Authors: Laura Marconato, Luca Aresu, Damiano Stefanello, Stefano Comazzi, Valeria Martini, Roberta Ferrari, Fulvio Riondato, Nicole Rouquet, Patrick Frayssinet and Silvia Sabattini

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:146

    Content type: Research article

    Published on:

  4. Talimogene laherparepvec is an oncolytic immunotherapy approved in the US, Europe, Australia and Switzerland. We report the final planned analysis of OPTiM, a randomized open-label phase III trial in patients ...

    Authors: Robert H. I. Andtbacka, Frances Collichio, Kevin J. Harrington, Mark R. Middleton, Gerald Downey, Katarina Ӧhrling and Howard L. Kaufman

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:145

    Content type: Short report

    Published on:

  5. Programmed death-ligand 1 (PD-L1) expression in metastatic renal cell carcinoma (RCC) correlates with a worse prognosis, but whether it also predicts responsiveness to anti-PD-1/PD-L1 therapy remains unclear. ...

    Authors: Joseph Vento, Aditi Mulgaonkar, Layton Woolford, Kien Nham, Alana Christie, Aditya Bagrodia, Alberto Diaz de Leon, Raquibul Hannan, Isaac Bowman, Renee M. McKay, Payal Kapur, Guiyang Hao, Xiankai Sun and James Brugarolas

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:144

    Content type: Case report

    Published on:

  6. Monoclonal antibodies (mAbs) mediate their effects in great part by inducing ADCC of NK cells, and multiple efforts aim to increase this function by engineering mAbs optimized Fc-parts. Even more potent antitu...

    Authors: Melanie Märklin, Ilona Hagelstein, Samuel P. Koerner, Kathrin Rothfelder, Martin S. Pfluegler, Andreas Schumacher, Ludger Grosse-Hovest, Gundram Jung and Helmut R. Salih

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:143

    Content type: Research article

    Published on:

  7. D2C7-IT is a novel immunotoxin (IT) targeting wild-type epidermal growth factor receptor (EGFRwt) and mutant EGFR variant III (EGFRvIII) proteins in glioblastoma. In addition to inherent tumoricidal activity, ...

    Authors: Vidyalakshmi Chandramohan, Xuhui Bao, Xin Yu, Scott Parker, Charlotte McDowall, Yen-Rei Yu, Patrick Healy, Annick Desjardins, Michael D. Gunn, Matthias Gromeier, Smita K. Nair, Ira H. Pastan and Darell D. Bigner

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:142

    Content type: Research article

    Published on:

  8. PD-1/PD-L1 inhibitors are promising approaches for advanced Merkel cell carcinoma (MCC). Nevertheless, these inhibitors bear a high risk for induction of immune-related adverse events (irAEs), particularly fla...

    Authors: Anne Zaremba, Eleftheria Chorti, Finja Jockenhöfer, Saskia Bolz, Selma Sirin, Martin Glas, Jürgen C. Becker, Selma Ugurel, Alexander Roesch, Dirk Schadendorf, Elisabeth Livingstone, Tim Hagenacker and Lisa Zimmer

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:141

    Content type: Case report

    Published on:

  9. Tumor-associated macrophages (TAM) are expanded and exhibit tumor-promoting properties within the tumor microenvironment. Current methods to study TAM have not been replicated across cancer types and often do ...

    Authors: Brooke Benner, Luke Scarberry, Lorena P. Suarez-Kelly, Megan C. Duggan, Amanda R. Campbell, Emily Smith, Gabriella Lapurga, Kallie Jiang, Jonathan P. Butchar, Susheela Tridandapani, John Harrison Howard, Robert A. Baiocchi, Thomas A. Mace and William E. Carson III

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:140

    Content type: Research article

    Published on:

  10. The tumor immune microenvironment has become the focus of research in clear cell renal cell carcinoma (ccRCC) due to its important role in immune surveillance post nephrectomy. This study investigates the corr...

    Authors: Pooja Ghatalia, Jennifer Gordetsky, Fengshen Kuo, Essel Dulaimi, Kathy Q. Cai, Karthik Devarajan, Sejong Bae, Gurudatta Naik, Timothy A. Chan, Robert Uzzo, A. Ari Hakimi, Guru Sonpavde and Elizabeth Plimack

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:139

    Content type: Research article

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2019 7:273

  11. Human natural killer (NK) cell lines serve as an attractive source for adoptive immunotherapy, but NK-92 remains the only cell line being assessed in the clinic. Here, we established a novel NK cell line, NK10...

    Authors: Hyun Gul Yang, Moon Cheol Kang, Tae Yoon Kim, Injung Hwang, Hyun Tak Jin, Young Chul Sung, Ki-Seong Eom and Sae Won Kim

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:138

    Content type: Research article

    Published on:

  12. Following publication of the original article [1], the author reported an author’s family name has been misspelled. Paul Engroff should be replace Paul Engeroff.

    Authors: Mona O. Mohsen, Matthew D. Heath, Gustavo Cabral-Miranda, Cyrill Lipp, Andris Zeltins, Marcos Sande, Jens V. Stein, Carsten Riether, Elisa Roesti, Lisha Zha, Paul Engeroff, Aadil El-Turabi, Thomas M. Kundig, Monique Vogel, Murray A. Skinner, Daniel E. Speiser…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:137

    Content type: Correction

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2019 7:114

  13. ONC201 is a small molecule antagonist of DRD2, a G protein-coupled receptor overexpressed in several malignancies, that has prolonged antitumor efficacy and immunomodulatory properties in preclinical models. T...

    Authors: Mark N. Stein, Jyoti Malhotra, Rohinton S. Tarapore, Usha Malhotra, Ann W. Silk, Nancy Chan, Lorna Rodriguez, Joseph Aisner, Robert D. Aiken, Tina Mayer, Bruce G. Haffty, Jenna H. Newman, Salvatore M. Aspromonte, Praveen K. Bommareddy, Ricardo Estupinian, Charles B. Chesson…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:136

    Content type: Research article

    Published on:

  14. Targeting epitopes derived from neo-antigens (or “neo-epitopes”) represents a promising immunotherapy approach with limited off-target effects. However, most peptides predicted using MHC binding prediction alg...

    Authors: Hanan Besser, Sharon Yunger, Efrat Merhavi-Shoham, Cyrille J. Cohen and Yoram Louzoun

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:135

    Content type: Research article

    Published on:

  15. Immune checkpoint inhibitors (ICI) produce durable antitumor responses but provoke autoimmune toxicities, including uncommon but potentially devastating neurologic toxicities. The clinical features, including ...

    Authors: Douglas B. Johnson, Ali Manouchehri, Alexandra M. Haugh, Henry T. Quach, Justin M. Balko, Benedicte Lebrun-Vignes, Andrew Mammen, Javid J. Moslehi and Joe-Elie Salem

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:134

    Content type: Research article

    Published on:

  16. Immune regulated pathways influence both breast cancer (BrC) development and response to (neo)adjuvant chemotherapy. The sentinel lymph node (SLN), as the first metastatic site, is also the first site where Br...

    Authors: Kim M. van Pul, Ronald J.C.L.M. Vuylsteke, Rieneke van de Ven, Elisabeth A. te Velde, Emiel J. Th. Rutgers, Petrousjka M. van den Tol, Hein B.A.C. Stockmann and Tanja D. de Gruijl

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:133

    Content type: Research article

    Published on:

  17. Immune checkpoint inhibitors are not effective for pancreatic ductal adenocarcinoma (PDAC) as single agents. Vaccine therapy may sensitize PDACs to checkpoint inhibitor treatments. Annexin A2 (ANXA2) is a pro-...

    Authors: Victoria M. Kim, Alex B. Blair, Peter Lauer, Kelly Foley, Xu Che, Kevin Soares, Tao Xia, Stephen T. Muth, Jennifer Kleponis, Todd D. Armstrong, Christopher L. Wolfgang, Elizabeth M. Jaffee, Dirk Brockstedt and Lei Zheng

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:132

    Content type: Research article

    Published on:

  18. Tumor immunology has changed the landscape of cancer treatment. Yet, not all patients benefit as cancer immune responsiveness (CIR) remains a limitation in a considerable proportion of cases. The multifactorial d...

    Authors: Davide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, Rongze Lu, Karolina Palucka, Josue Samayoa, Stefani Spranger, Sarah Warren, Kwok-Kin Wong, Elad Ziv, Diego Chowell, Lisa M. Coussens, Daniel D. De Carvalho, David G. DeNardo, Jérôme Galon, Howard L. Kaufman…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:131

    Content type: Review

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2019 7:167

  19. Patients with human immunodeficiency virus (HIV) infection have a high risk of developing virally-mediated cancers. These tumors have several features that could make them vulnerable to immune checkpoint inhib...

    Authors: Jacob J. Adashek, Pedro Nazareth Aguiar Junior, Natalie Galanina and Razelle Kurzrock

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:130

    Content type: Commentary

    Published on:

  20. The rapid development of immuno-oncology (I-O) therapies for multiple types of cancer has transformed the cancer treatment landscape and brightened the long-term outlook for many patients with advanced cancer....

    Authors: Howard L. Kaufman, Michael B. Atkins, Prasun Subedi, James Wu, James Chambers, T. Joseph Mattingly II, Jonathan D. Campbell, Jeff Allen, Andrea E. Ferris, Richard L. Schilsky, Daniel Danielson, J. Leonard Lichtenfeld, Linda House and Wendy K. D. Selig

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:129

    Content type: Position article and guidelines

    Published on:

  21. The immunogenomic changes triggered by concurrent chemoradiation therapy (CCRT), a standard neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC), are unknown. We aimed to analyz...

    Authors: Sehhoon Park, Je-Gun Joung, Yang Won Min, Jae-Yong Nam, Daeun Ryu, Dongryul Oh, Woong-Yang Park, Se-Hoon Lee, Yoon La Choi, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park and Jong-Mu Sun

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:128

    Content type: Research article

    Published on:

  22. Nivolumab is approved for mRCC patients who have received prior anti-angiogenic therapy but the duration of therapy required for sustained clinical benefit is unknown. A phase II clinical trial to investigate ...

    Authors: Moshe C. Ornstein, Laura S. Wood, Brian P. Hobbs, Kimberly D. Allman, Allison Martin, Michael Bevan, Timothy D. Gilligan, Jorge A. Garcia and Brian I. Rini

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:127

    Content type: Short report

    Published on:

  23. Despite ground-breaking clinical success in the treatment of different cancers, immune checkpoint inhibitors can cause profound inflammatory and immune-related adverse events. Autoimmune inflammatory arthritis...

    Authors: Sang T. Kim, Mohamad Bittar, Hyun J. Kim, Sattva S. Neelapu, Amado J. Zurita, Roza Nurieva and Maria E. Suarez-Almazor

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:126

    Content type: Case report

    Published on:

  24. Insertion–deletion mutations (indels) may generate more tumour-specific neoantigens with high affinity to major histocompatibility complex class I. A high indel ratio is also related to a good response to prog...

    Authors: Minghao Sui, Yu Li, Hongguang Wang, Ying Luo, Tao Wan, Xun Wang, Bingyang Hu, Yanshuang Cheng, Xianrong Lv, Xianlei Xin, Qiang Xu, Guan Wang and Shichun Lu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:125

    Content type: Case report

    Published on:

  25. Following publication of the original article [1], the author reported the wrong version of Figs. 5 and 7 have been published. The correct version of the figures can be found below:

    Authors: Elena E. Tchekneva, Mounika U. L. Goruganthu, Roman V. Uzhachenko, Portia L. Thomas, Anneliese Antonucci, Irina Chekneva, Michael Koenig, Longzhu Piao, Anwari Akhter, Maria Teresa P. de Aquino, Parvathi Ranganathan, Nicholas Long, Thomas Magliery, Anna Valujskikh, Jason V. Evans, Rajeswara R. Arasada…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:124

    Content type: Correction

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2019 7:95

  26. The progression of cancer requires mutational adaptation to permit unrestrained proliferation. A fraction of cancer mutations are oncogenic drivers, while others are putative ‘passengers’ that do not contribut...

    Authors: Yu Wang, Douglas B. Johnson, Steve Lu, Luis A. Diaz Jr, Yaomin Xu and Justin M. Balko

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:123

    Content type: Short report

    Published on:

  27. High-risk human papillomavirus (HPV) are responsible for genital and oral cancers associated with the expression of the E6/E7 HPV oncogenes. Therapeutic vaccines targeting those oncogenes can only partially co...

    Authors: Sonia Domingos-Pereira, Gabriele Galliverti, Douglas Hanahan and Denise Nardelli-Haefliger

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:122

    Content type: Short report

    Published on:

  28. Immune checkpoint therapies (ICTs) targeting the programmed cell death-1 (PD1)/programmed cell death ligand-1 (PD-L1) pathway have improved outcomes for patients with non-small cell lung cancer (NSCLC), partic...

    Authors: Sonja Althammer, Tze Heng Tan, Andreas Spitzmüller, Lorenz Rognoni, Tobias Wiestler, Thomas Herz, Moritz Widmaier, Marlon C. Rebelatto, Helene Kaplon, Diane Damotte, Marco Alifano, Scott A. Hammond, Marie-Caroline Dieu-Nosjean, Koustubh Ranade, Guenter Schmidt, Brandon W. Higgs…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:121

    Content type: Research article

    Published on:

  29. Pembrolizumab monotherapy has become the preferred treatment for patients with advanced non-small cell lung carcinoma (NSCLC) and a programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS) of at lea...

    Authors: Yixin Zhou, Zuan Lin, Xuanye Zhang, Chen Chen, Hongyun Zhao, Shaodong Hong and Li Zhang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:120

    Content type: Commentary

    Published on:

  30. Recurrent respiratory papillomatosis (RRP) is a human papillomavirus (HPV)-driven disorder that causes substantial morbidity and can lead to fatal distal airway obstruction and post-obstructive pneumonias. Pat...

    Authors: Clint T. Allen, Sunmin Lee, Scott M. Norberg, Damian Kovalovsky, Hong Ye, Paul E. Clavijo, Siwen Hu-Lieskovan, Richard Schlegel, Jeffrey Schlom, Julius Strauss, James L. Gulley, Jane Trepel and Christian S. Hinrichs

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:119

    Content type: Research article

    Published on:

  31. Immune checkpoint inhibitors (ICIs) represent a promising novel class of cancer therapy, but immune-mediated adverse events can complicate ICI treatment. Acute cholecystitis in patients receiving ICI therapy h...

    Authors: Hamzah Abu-Sbeih, Cynthia Nguyen Tran, Phillip S. Ge, Manoop S. Bhutani, Mazen Alasadi, Aung Naing, Amir A. Jazaeri and Yinghong Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:118

    Content type: Research article

    Published on:

  32. Immune checkpoint inhibitor (ICI) use in clinical practice has unravelled a spectrum of immune-related adverse events (irAEs) due to immune system hyper-activation. ICI-related haemophagocytic lymphohistiocyto...

    Authors: Roberta Noseda, Raffaela Bertoli, Laura Müller and Alessandro Ceschi

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:117

    Content type: Short report

    Published on:

  33. Poly I:C is a powerful immune adjuvant as a result of its agonist activities on TLR-3, MDA5 and RIG-I. BO-112 is a nanoplexed formulation of Poly I:C complexed with polyethylenimine that causes tumor cell apop...

    Authors: M. Angela Aznar, Lourdes Planelles, Mercedes Perez-Olivares, Carmen Molina, Saray Garasa, Iñaki Etxeberría, Guiomar Perez, Inmaculada Rodriguez, Elixabet Bolaños, Pedro Lopez-Casas, Maria E. Rodriguez-Ruiz, Jose L. Perez-Gracia, Ivan Marquez-Rodas, Alvaro Teijeira, Marisol Quintero and Ignacio Melero

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:116

    Content type: Research article

    Published on:

  34. Pancreatic cancer is characterized by an immune suppressive stromal reaction that creates a barrier to therapy. A murine transgenic pancreatic cancer cell line that recapitulates human disease was used to test...

    Authors: Weiqing Jing, Donna McAllister, Emily P. Vonderhaar, Katie Palen, Matthew J. Riese, Jill Gershan, Bryon D. Johnson and Michael B. Dwinell

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:115

    Content type: Research article

    Published on:

  35. Induction of strong T cell responses, in particular cytotoxic T cells, is a key for the generation of efficacious therapeutic cancer vaccines which yet, remains a major challenge for the vaccine developing wor...

    Authors: Mona O. Mohsen, Matthew D. Heath, Gustavo Cabral-Miranda, Cyrill Lipp, Andris Zeltins, Marcos Sande, Jens V. Stein, Carsten Riether, Elisa Roesti, Lisha Zha, Paul Engeroff, Aadil El-Turabi, Thomas M. Kundig, Monique Vogel, Murray A. Skinner, Daniel E. Speiser…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:114

    Content type: Research article

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2019 7:137

  36. Cancer vaccines are designed to promote systemic antitumor immunity and tumor eradication. Cancer vaccination may be more efficacious in combination with additional interventions that may build on or amplify t...

    Authors: Lisa H. Butterfield, Lazar Vujanovic, Patricia M. Santos, Deena M. Maurer, Andrea Gambotto, Joel Lohr, Chunlei Li, Jacob Waldman, Uma Chandran, Yan Lin, Huang Lin, Hussein A. Tawbi, Ahmad A. Tarhini and John M. Kirkwood

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:113

    Content type: Research article

    Published on:

  37. Pneumonitis is a potential consequence of both lung-directed radiation and immune checkpoint blockade (ICB), particularly treatment with PD-1/PD-L1 inhibitors. Significant morbidity and mortality can result, a...

    Authors: Jonathan D. Schoenfeld, Mizuki Nishino, Mariano Severgnini, Michael Manos, Raymond H. Mak and F. Stephen Hodi

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:112

    Content type: Case report

    Published on:

  38. Dysregulation in calcium (Ca2+) signaling is a hallmark of chronic lymphocytic leukemia (CLL). While the role of the B cell receptor (BCR) Ca2+ pathway has been associated with disease progression, the importance...

    Authors: Marjolaine Debant, Miguel Burgos, Patrice Hemon, Paul Buscaglia, Tinhinane Fali, Sarra Melayah, Nelig Le Goux, Christophe Vandier, Marie Potier-Cartereau, Jacques-Olivier Pers, Adrian Tempescul, Christian Berthou, Cristina Bagacean, Olivier Mignen and Yves Renaudineau

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:111

    Content type: Research article

    Published on:

  39. The colorectal cancer antigen GUCY2C exhibits unique split tolerance, evoking antigen-specific CD8+, but not CD4+, T-cell responses that deliver anti-tumor immunity without autoimmunity in mice. Here, the cancer ...

    Authors: Adam E. Snook, Trevor R. Baybutt, Bo Xiang, Tara S. Abraham, John C. Flickinger Jr, Terry Hyslop, Tingting Zhan, Walter K. Kraft, Takami Sato and Scott A. Waldman

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:104

    Content type: Research article

    Published on:

  40. Malignant pleural effusions (MPE) are a common terminal pathway for many cancers, with an estimated United States incidence of more than 150,000 cases per year. MPE is an aggressive disease with a uniformly fa...

    Authors: Albert D. Donnenberg, James D. Luketich, Rajeev Dhupar and Vera S. Donnenberg

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:110

    Content type: Commentary

    Published on:

  41. Dendritic cells (DCs) can initiate and direct adaptive immune responses. This ability is exploitable in DC vaccination strategies, in which DCs are educated ex vivo to present tumor antigens and are administer...

    Authors: Kalijn F. Bol, Gerty Schreibelt, Katrin Rabold, Stefanie K. Wculek, Julia Katharina Schwarze, Andrzej Dzionek, Alvaro Teijeira, Lana E. Kandalaft, Pedro Romero, George Coukos, Bart Neyns, David Sancho, Ignacio Melero and I. Jolanda M. de Vries

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:109

    Content type: Review

    Published on:

  42. The activity of the commensal microbiota significantly impacts human health and has been linked to the development of many diseases, including cancer. Gnotobiotic animal models have shown that the microbiota h...

    Authors: Jessica Fessler, Vyara Matson and Thomas F. Gajewski

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:108

    Content type: Review

    Published on:

  43. Following publication of the original article [1], the authors reported an error in their listed affiliations.

    Authors: Daniel H. Johnson, Chrystia M. Zobniw, Van A. Trinh, Junsheng Ma, Roland L. Bassett Jr, Noha Abdel-Wahab, Jaime Anderson, Jennifer E. Davis, Jocelyn Joseph, Marc Uemura, Ali Noman, Hamzah Abu-Sbeih, Cassian Yee, Rodabe Amaria, Sapna Patel, Hussein Tawbi…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:107

    Content type: Correction

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2018 6:103

  44. Checkpoint inhibitors (CPIs) have revolutionized the treatment of cancer, but their use remains limited by off-target inflammatory and immune-related adverse events. Solid organ transplantation (SOT) recipient...

    Authors: Noha Abdel-Wahab, Houssein Safa, Ala Abudayyeh, Daniel H. Johnson, Van Anh Trinh, Chrystia M. Zobniw, Heather Lin, Michael K. Wong, Maen Abdelrahim, A. Osama Gaber, Maria E. Suarez-Almazor and Adi Diab

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:106

    Content type: Research article

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2019 7:158

  45. The increasing use of multiple immunomodulatory (IMD) agents for cancer therapies (e.g. antibodies targeting immune checkpoints, bispecific antibodies, and chimeric antigen receptor [CAR]-T cells), is raising ...

    Authors: Jasmine Davda, Paul Declerck, Siwen Hu-Lieskovan, Timothy P. Hickling, Ira A. Jacobs, Jeffrey Chou, Shahram Salek-Ardakani and Eugenia Kraynov

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:105

    Content type: Review

    Published on:

  46. The T cell bispecific antibody cibisatamab (CEA-TCB) binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells, which triggers T cell killing of cancer cell lines expressing moderate to high lev...

    Authors: Reyes Gonzalez-Exposito, Maria Semiannikova, Beatrice Griffiths, Khurum Khan, Louise J. Barber, Andrew Woolston, Georgia Spain, Katharina von Loga, Ben Challoner, Radhika Patel, Michael Ranes, Amanda Swain, Janet Thomas, Annette Bryant, Claire Saffery, Nicos Fotiadis…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:101

    Content type: Research article

    Published on:

  47. The CTLA-4 blocking antibody ipilimumab has demonstrated substantial and durable effects in patients with melanoma. While CTLA-4 therapy, both as monotherapy and in combination with PD-1 targeting therapies, h...

    Authors: Anne Månsson Kvarnhammar, Niina Veitonmäki, Karin Hägerbrand, Anna Dahlman, Karin Enell Smith, Sara Fritzell, Laura von Schantz, Mia Thagesson, Doreen Werchau, Kristine Smedenfors, Maria Johansson, Anna Rosén, Ida Åberg, Magnus Winnerstam, Eva Nyblom, Karin Barchan…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:103

    Content type: Research article

    Published on:

  48. To investigate the efficacy and safety of concurrent stereotactic radiosurgery (SRS) and ipilimumab or nivolumab in patients with untreated melanoma brain metastases.

    Authors: Giuseppe Minniti, Dimitri Anzellini, Chiara Reverberi, Gian Carlo Antonini Cappellini, Luca Marchetti, Federico Bianciardi, Alessandro Bozzao, Mattia Osti, Pier Carlo Gentile and Vincenzo Esposito

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:102

    Content type: Research article

    Published on:

  49. How the immune microenvironment changes during neoadjuvant chemotherapy of primary breast cancer is not well understood.

    Authors: Xiaotong Li, Sarah Warren, Vasiliki Pelekanou, Vikram Wali, Alessandra Cesano, Mingdong Liu, Patrick Danaher, Nathane Elliott, Zeina A. Nahleh, Daniel F. Hayes, Gabriel N. Hortobagyi, William E. Barlow, Christos Hatzis and Lajos Pusztai

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:88

    Content type: Research article

    Published on:

  50. The manipulation of dendritic cells (DCs) for cancer vaccination has not reached its full potential, despite the revolution in cancer immunotherapy. DCs are fundamental for CD8+ T cell activation, which relies...

    Authors: Stefanie K. Wculek, Joaquín Amores-Iniesta, Ruth Conde-Garrosa, Sofía C. Khouili, Ignacio Melero and David Sancho

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:100

    Content type: Research article

    Published on:

Annual Journal Metrics

Advertisement